Alliancebernstein L.P. Sells 599,785 Shares of Illumina, Inc. (NASDAQ:ILMN)

Alliancebernstein L.P. lessened its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 26.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,688,859 shares of the life sciences company’s stock after selling 599,785 shares during the period. Alliancebernstein L.P. owned approximately 1.06% of Illumina worth $225,682,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the company. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the fourth quarter worth $32,000. Versant Capital Management Inc boosted its position in shares of Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina during the fourth quarter worth about $45,000. Assetmark Inc. grew its holdings in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Finally, Lee Danner & Bass Inc. purchased a new stake in Illumina in the fourth quarter valued at approximately $48,000. 89.42% of the stock is owned by institutional investors.

Illumina Price Performance

ILMN opened at $79.34 on Tuesday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a market capitalization of $12.57 billion, a PE ratio of -10.33, a price-to-earnings-growth ratio of 1.60 and a beta of 1.17. The stock’s 50 day moving average price is $101.65 and its 200-day moving average price is $126.49. Illumina, Inc. has a 52-week low of $77.54 and a 52-week high of $156.66.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, equities research analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and decreased their price target for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Barclays reissued an “underweight” rating on shares of Illumina in a research note on Tuesday, March 11th. Citigroup dropped their price target on Illumina from $130.00 to $90.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Guggenheim reduced their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Royal Bank of Canada dropped their target price on Illumina from $247.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $140.90.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.